From left to right: Andrew M. Evens, Linda Tanzer and Eileen WhiteAndrew M. Evens and Linda Tanzer were named to expanded deputy director positions at Rutgers Cancer Institute of New Jersey.
George Raptis was named director of Oncology Services for the Northern Region at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. Raptis will also care for patients at Cooperman Barnabas Medical Center, an RWJBarnabas Health facility.
Eric McKeeby was named head of communications and marketing at the Parker Institute for Cancer Immunotherapy.
Washington University School of Medicine in St. Louis received a five-year, $7.8 million grant from NIH to support a radiation oncology center that is part of a select national network of centers aimed at understanding the biologic effects of radiation therapy in cancer treatment.
The University of Arkansas for Medical Sciences met its $30 million fundraising goal for the Winthrop P. Rockefeller Cancer Institute’s campaign to achieve NCI designation.
Onyinye Balogun and Stephanie Rieder were named Health Equity Fellows by NRG Oncology, an NCI National Clinical Trials Network group as a part of the organization’s Health Equity Fellowship Program.
Eric SmithAndrew AguirreSam KlempnerThe DeGregorio Family Foundation, with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative, or GEMINI, awarded $300,000 to Eric Smith and Andrew Aguirre, both of Dana-Farber Cancer Institute, and Sam Klempner, of Massachusetts General Hospital, to reward the progress they have made on their grant in a little over a year.
The National Comprehensive Cancer Network, American Cancer Society Cancer Action Network, and the National Minority Quality Forum established three key areas of policy focus as part of the Alliance for Cancer Care Equity joint collaboration, including advancing diversity in clinical trials, improving cancer screening and early detection, and increasing access to patient navigation.
On the two-year anniversary of the reignited Cancer Moonshot Feb. 2, the American Cancer Society Cancer Action Network called on the White House and Congress to reinforce their commitment to end cancer as we know it by taking key steps to prioritize cancer prevention and research.
FDA accepted the supplemental Biologics Application for neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage 2A to 3B non-small cell lung cancer. FDA assigned a Prescription Drug User Fee Act goal date of Oct. 8.
